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Background
Preclinical safety testing for adoptive immunotherapies uti-
lising T cell receptor-(TCR) engineered T cells relies on
stringent target validation and a robust pre-clinical specifi-
city testing strategy. Specific safety concerns include on-
target off-tumour toxicity and off-target toxicity. Avoidance
of these toxicities requires that the expression profile of the
target antigen be shown to be specific to tumour tissues,
and that the TCR is shown to be specific.
Methods
We evaluated the cancer testis antigen, MAGE-A10 (mela-
noma antigen family A10). Mage-A10 was found to be
expressed in multiple tumour samples including lung [all
indications] (16.4%, 23/140), lung squamous cell carci-
noma (30.4%, 14/46) and breast (2.2%, 3/135). Mage-A10
RNA expression was measured across 72 normal tissues
(3 samples each), and no expression was detected outside
of placenta and very low expression was detected in testis,
an immune privileged site. Thus, we concluded Mage-A10
was an attractive tumour target.
Results
21 parental TCRs specific for the selected HLA-A2
restricted Mage-A10 peptide, were identified; three were
selected for affinity enhancement. Fifteen affinity-
enhanced TCRs were screened in cell based assays
against a panel of tumour cells lines +/- for HLA-A2
and/or Mage-A10 expression, resulting in the selection
of two candidates based on potency and specificity in
ELISpot assays. To establish the fine specificity of each
TCR, a peptide binding motif was established, using a
panel of 172 peptides representing substitution of each
amino acid position with all other possible amino acids,
and searched against the human genome. Mage-A10
clone 796 (Mage-A10c796) was selected based on this
molecular mapping, which demonstrated only 3 other
peptides that the TCR could potentially recognize; none
were subsequently recognized in cell based assays, thus
demonstrating the specificity of Mage-A10c796. T cells
expressing Mage-A10c796 (Mage-A10c796–T) were
screened against 59 HLA-A2 positive normal cells and
22 MAGE-A10 negative tumour cell lines by IFN-g ELI-
Spot, and no off-target reactivity was revealed. Potential
alloreactivity of Mage-A10c796–T was tested using a
panel of 67 B cell lines expressing 129 different HLA
alleles. Alloreactivity against HLA-B*1501 and B*4601
was identified. These alleles will form part of exclusion
criteria for clinical trials. Additional assays performed to
assess potential cytotoxicity and cytokine release all
demonstrated good on-target potency with no identified
on- or off-target safety concerns.
Conclusions
These data support the clinical application of Mage-
A10c796–T. The IND is now open and a dose escalation
study in lung cancer is due to start in the second half of
2015.
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